Gluten-sensitive enteropathy : more common than you think – celiac disease
David A. Nelsen, Jr.
Although celiac disease was formally described late in the 19th century, treatment remained empiric until the middle of the 20th century when patients were noted to improve dramatically after wheat was removed from their diet. With the development of small-bowel biopsy techniques, the small intestine was identified as the target organ. Disease causality was established when the characteristic features of villous flattening, crypt hyperplasia, and increased intraepithelial lymphocytes (Figure 1) were shown to normalize after the institution of a gluten-free diet. (1)
In the mid-1960s, an enteropathy strikingly similar to celiac disease was identified in patients with dermatitis herpetiformis. Subsequently, this skin disorder was shown to be a manifestation of gluten-sensitive enteropathy. In the mid-1960s, adult celiac disease was also noted to be associated with numerous neurologic disorders, including epilepsy, cerebral calcifications, and peripheral neuropathy. (1)
Recent population studies indicate that celiac disease is more common than was previously thought. Some patients with gluten-sensitive enteropathy have minimal or no symptoms and are unlikely to be referred to a gastroenterologist unless the disease is considered. Hence, family physicians need to be familiar with the diagnosis and management of gluten-sensitive enteropathy.
Ingested protein does not normally provoke an immune response. This phenomenon is termed “oral tolerance.” Patients who exhibit true allergy to an ingested protein (e.g., milk or soy protein) have a typical IgE-mediated response consisting of urticaria, angioedema, and bronchoreactivity.
The autoimmunity in gluten-sensitive enteropathy involves plasma cells that produce IgA and IgG; there is little or no IgE involvement. Current theory suggests that ingested a-gliadin (a component of the gluten protein) and related peptides bind with tissue transglutaminase (a ubiquitous intracellular enzyme) in enterocytes. The a-gliadin is rich in glutamine; transglutaminase deamidates glutamine residues, forming glutamic acid. Deamidation enhances the immunogenicity of a-gliadin by creating epitopes that are recognized as foreign by host cell-mediated immunity. (2)
Plasma cells produce IgA and IgG that are directed against a variety of antigens, including transglutaminase, endomysium, gliadin, and reticulin. Locally elaborated lymphokines attract inflammatory cells. (3) This intense local inflammatory reaction produces the villous flattening characteristic of gluten-sensitive enteropathy. Malabsorption of micronutrients (e.g., vitamins and minerals) and macronutrients (e.g., protein, carbohydrate, fat) follows. Small-bowel involvement is most prominent proximally and may be “patchy,” especially in patients with “silent” celiac disease (i.e., minimal or no symptoms) and those with dermatitis herpetiformis.
Approximately 95 percent of patients with celiac disease exhibit specific Human Leukocyte Antigen (HLA) class II alleles DQA1*0501 and DQB1*0201. (4) Patients with type 1 diabetes, autoimmune thyroid disease, (5) Sjogren’s syndrome, primary biliary cirrhosis, Addison’s disease, systemic lupus erythematosus, selective IgA deficiency, and alopecia areata may also exhibit similar genotypes and are at risk for gluten-sensitive enteropathy (Table 1). Because many persons have these genotypes and only a few develop gluten-sensitive enteropathy, investigators have hypothesized that other genes or cofactors may be involved. (1)
Until recently, celiac disease was considered to be relatively uncommon. Previous U.S. figures suggested that it affected one in 6,000 persons. (6) However, population studies published in the past four years suggest a much higher prevalence, particularly in persons of European ancestry. (7) Studies conducted in Europe estimate the seroprevalence of celiac disease to be one case per 130 to 300 persons. (8-10)
In a recent U.S. study, (11) investigators tested sera from 2,000 healthy Red Cross blood donors and found eight samples that were positive for antibodies associated with gluten-sensitive enteropathy (seven samples from white persons, one sample from a black person). The seroprevalence rate in this study (one case per 250 persons tested) is consistent with the rates in European studies.
The likelihood of having gluten-sensitive enteropathy increases to 10 to 20 percent in persons who have a first-degree relative with celiac disease. (1) In addition, celiac disease is associated with other autoimmune syndromes. For example, as many as 7 percent of patients with type I diabetes also have gluten-sensitive enteropathy. (12)
Untreated gluten-sensitive enteropathy is associated with a range of symptoms13,14 (Table 2). The “classic” form typically presents in infancy and manifests as failure to thrive, diarrhea, abdominal distention, developmental delay, and, occasionally, severe malnutrition. Failure to diagnose the disorder may lead to a true medical emergency.
Beyond infancy, the symptoms of celiac disease tend to be less dramatic. Older children may present with constitutional short stature or dental enamel defects.
Women comprise approximately 75 percent of newly diagnosed adult celiac disease cases. Women also tend to have more clinically conspicuous disease. (15) In adults of both sexes, gastrointestinal tract involvement may manifest as diarrhea, constipation, or other symptoms of malabsorption, such as bloating, flatus, or belching. Fatigue, depression, fibromyalgia-like symptoms, aphthous stomatitis, bone pain, dyspepsia, gastroesophageal reflux, and other nonspecific symptoms may be present and can make the diagnosis quite challenging. (14) A number of other autoimmune syndromes have been associated with celiac disease (Table 1).
Fewer than 10 percent of adults with gluten-sensitive enteropathy present with dermatitis herpetiformis. (16) This skin condition may be misdiagnosed as atypical psoriasis or nonspecific dermatitis.
The rash of dermatitis herpetiformis is intensely pruritic and typically occurs on the back, buttocks, knees, and elbows (Figure 2). Unexcoriated lesions (Figure 3) are remarkably like those of herpes simplex (thus, the term “herpetiformis”). Granular IgA deposition on immunofluorescence of a skin biopsy specimen is diagnostic (Figure 4).
Anemia is the most common laboratory manifestation of celiac disease (13,14) (Table 3). One half of patients with newly diagnosed gluten-sensitive enteropathy are anemic. Iron is absorbed in the proximal small intestine, where celiac manifestations are most prominent; hence, iron malabsorption is common. In addition, occult blood loss related to intense small-bowel inflammation may occur in 50 percent of patients with gluten-sensitive enteropathy. (17) Less commonly, vitamin B12 deficiency, folate deficiency, or both may be present.
SILENT CELIAC DISEASE
A number of investigators believe that clinically apparent gluten-sensitive enteropathy represents the “tip of the iceberg” of the overall disease burden. (7) Patients who were detected in the seroprevalence studies (8-11) were asymptomatic or oligosymptomatic (so-called “silent” celiac disease).
Family physicians should consider serologic testing in patients with the following: family history of celiac disease, personal history of thyroid disease or type I diabetes, irritable bowel syndrome, anemia (especially iron deficiency), chronic diarrhea, chronic fatigue, unexplained weight loss, short stature, epilepsy, infertility, (18) or unexplained elevation of transaminase levels. Asymptomatic or oligosymptomatic patients are still at risk for complications of celiac disease.
When the diagnosis of gluten-sensitive enteropathy is suspected, serologic tests can identify many affected patients. (19) (Figure 5). IgA antiendomysial antibody has been shown to be 85 to 100 percent sensitive and 96 to 100 percent specific for celiac disease. IgA antiendomysial antibody is measured using direct immunofluorescence of monkey esophagus or umbilical cord tissue processed with suspect serum.
[FIGURE 5 OMITTED]
IgG and IgA antigliadin antibodies are also useful in diagnosing celiac disease. The antibody directed against endomysium has recently been identified as identical to the antibody directed against (tissue) transglutaminase. An enzyme-linked immunosorbent assay has been developed to measure IgA antitransglutaminase; this test will generally replace the more tedious direct fluorescent antibody test for IgA antiendomysial antibody. (20-22) In diagnosing celiac disease, antitransglutaminase antibody is considered to be approximately as sensitive and specific as antiendomysial antibody (Table 4). (21,23-25)
The presence of IgA antiendomysial and antitransglutaminase antibodies correlates with intestinal damage. Tests for these antibodies are highly sensitive in patients with total and subtotal villous atrophy. IgA antiendomysial antibody testing has been reported to be 100 percent sensitive in patients with total villous atrophy. The combination of IgA antiendomysial antibody and IgG and IgA antigliadin antibodies detects 76 percent of patients with mucosal damage.
It is important to note that 2 to 3 percent of patients with gluten-sensitive enteropathy also have selective IgA deficiency. Because these patients may not produce the diagnostic IgA antibodies, a positive IgG antigliadin antibody test may be the only serologic evidence of the disease. If clinical suspicion is high, quantitative IgA measurements should be obtained in these patients. (26) Endoscopy and biopsy should be strongly considered in patients with selective IgA deficiency.
Declining autoantibody titers correlate with resolution of the gastrointestinal lesion and may be used to document clinical improvement. In equivocal cases or when a patient has been on a gluten-free diet, a gluten challenge test may be used to provoke the gastrointestinal lesion and serologic response.
DISTAL DUODENAL BIOPSY
Distal duodenal biopsy is the gold standard for the diagnosis of celiac disease. Biopsy should be performed in most patients with suspected gluten-sensitive enteropathy. In determining the need for biopsy, family physicians should consult a gastroenterologist who is experienced in the diagnosis and management of celiac disease. (1)
Calcium and vitamin D malabsorption dramatically increases the risk of osteoporosis and osteomalacia in patients with gluten-sensitive enteropathy. Most patients with celiac disease have some degree of osteopenia or osteoporosis. Fortunately, calcium and vitamin D supplementation, coupled with a strict gluten-free diet, usually results in remineralization of the skeleton. (27,28)
Bone density should be assessed in all patients with newly diagnosed celiac disease. Postmenopausal women should be advised about the benefits of estrogen replacement. The use of antiresorptive agents (e.g., alendronate [Fosamax]) has not been extensively studied, but these drugs may be of benefit.
Cerebral calcifications and epilepsy have been associated with celiac disease (29,30) and do not always resolve with the institution of a gluten-free diet. Peripheral neuropathy, postural instability, “gluten ataxia,” and other vague neurologic complaints may be the sole manifestation of gluten-sensitive enteropathy. (31) Autoantibodies associated with celiac disease have demonstrated a strong affinity for brain vasculature. (32)
In patients with refractory sprue, gastrointestinal tract inflammation continues despite maintenance of a gluten-free diet. Dietary noncompliance is the most common reason for persistent inflammation; however, coexistent conditions such as hyperthyroidism and collagenous colitis should also be considered.
Patients who are truly refractory to dietary measures may have cryptic lymphoma of (bowel) intraepithelial lymphocytes. All diet-refractory patients should be evaluated by a gastroenterologist with expertise in the management of celiac disease. Corticosteroids and immunosuppressant drugs have been used to treat refractory sprue, but data on their effectiveness are sparse.
Intestinal strictures and bowel obstruction may develop in patients with refractory sprue or celiac disease that has been untreated over a long period.
LYMPHOMA AND BOWEL ADENOCARCINOMA
Enteropathy-associated T-cell lymphoma has been associated with untreated gluten-sensitive enteropathy and refractory sprue. (33) Lymphoma may develop in patients with celiac disease who also have dermatitis herpetiformis.
Studies (34,35) have shown that maintenance of a long-term gluten-free state reduces the risk of lymphoma to the level in the general population. Thus, it is imperative that patients with celiac disease (and dermatitis herpetiformis) maintain a gluten-free diet for the rest of their lives.
Patients with celiac disease are also at risk for the development of bowel adenocarcinoma in all sites. The risk is especially high in patients with a long period of disease preceding institution of a gluten-free diet.
Once the diagnosis of celiac disease has been made, patients should be evaluated for known manifestations and complications (Table 5). Iron deficiency should be treated with supplemental iron. Osteoporosis should be treated with calcium and vitamin D replacement. Depending on individual factors, patients with gluten-sensitive enteropathy may need to take a multivitamin, iron, calcium, magnesium, zinc, selenium, vitamin D, or other nutrients.
The primary treatment for celiac disease is the removal of gluten and related proteins from the diet. Complete exclusion of dietary gluten generally results in rapid and complete healing of small-bowel inflammation. Advice from a registered dietitian is essential to outline an appropriate diet.
Gluten, a prolamine, is the primary protein in wheat. Hence, wheat and products containing wheat must be avoided. Barley and rye contain similar proteins and must also be avoided. Oats are a subject of controversy. (36,37) Although oats themselves may be nontoxic in limited quantities, commercial oat products are measurably contaminated with wheat. Rice, corn, maize, flax, quinoa, tapioca, potato, amaranth, and other grain substitutes, such as nuts and beans, are safe.
There are many commercial gluten-free products, including breads, cookies, chips, and cereals, that can be used to fashion a rich and interesting diet. Meats, vegetables, fruit, and most dairy products are free of gluten, as long as they have not been contaminated during production.
A number of food manufacturers maintain lists of gluten-free products. These lists can be obtained from the manufacturers’ Web sites or by telephone request. Information on gluten-free foods is also available from local or national support groups such as the Celiac Sprue Association. Selected resources are provided in Table 6.
Celiac Disease and Other Autoimmune Disorders *
Type 1 diabetes mellitus
Autoimmune thyroid disease
Systemic lupus erythematosus
Autoimmune Addison’s disease
Recurrent aphthous ulcerations
Vitiligo or alopecia areata
*–Listed in descending order of clinical importance and prevalence.
Symptoms of Celiac Disease and Possible Causes
Symptoms Possible causes
Fatigue, malaise Anemia, general immune system
Weight loss Nutrient malabsorption
Diarrhea, abdominal Accelerated gastrointestinal tract
pain transit time, steatorrhea,
Anemia Most commonly, iron deficiency; less
commonly, vitamin [B.sub.12] and/or folate
Bone pain Osteoporosis
Aphthous oral ulcers, Vitamin deficiency, “oral” celiac disease
Infertility Postulated cause: iron, folate, and/or
Male impotence, Peripheral insensitivity to circulating
decreased libido testosterone
Alopecia areata Immunologic attack on hair follicles
Dental enamel defects Demineralization during tooth bud
development in children
Hypoglycemia Delayed absorption of glucose
Gas, flatus, borborygmus Secondary digestion of sugars by
Seizures, gluten ataxia, Increased affinity of celiac antibodies
central nervous system for brain vasculature
Abnormal Laboratory Findings in Celiac Disease
Laboratory finding Pathophysiology
Anemia Iron deficiency;
and/or folate deficiency
Elevated alkaline phosphatase Osteoporosis, osteomalacia
Elevated aspartate transaminase Minimal elevation common
and alanine transaminase in celiac disease; presumably
Decreased albumin level Malnutrition
Elevated calcium level, decreased Vitamin D deficiency, secondary
phosphate level hyperparathyroidism
Thrombocytosis, leukocytosis General inflammatory reaction
Coagulopathy Decreased vitamin K absorption
Low high-density and low-density Decreased fat absorption,
lipoprotein cholesterol levels decreased hepatic
Serologic Tests for Celiac Disease
Antibody test Sensitivity (%) Specificity (%)
IgA antiendomysial 85 to 100 96 to 100
IgA antitransglutaminase 95 90
IgA antigliadin antibody 53 to 100 65 to 100
IgG antigliadin antibody 57 to 100 42 to 98
Antibody test Time course
IgA antiendomysial Antibody disappears within several
antibody months after institution of
IgA antitransglutaminase Limited data; correlated with
antibody IgA antiendomysial
antibody in studies
IgA antigliadin antibody More persistent than
IgA antiendomysial antibody;
may persist for 6 months or longer
IgG antigliadin antibody Most persistent; may be
detectable up to 12 months
after institution of gluten-free diet
False-positive tests reported in patients
with Crohn’s disease, wheat-protein
allergy, and postdiarrhea states
Antibody test Cost *
IgA antiendomysial $45 to 99
IgA antitransglutaminase 85 to 164
IgA antigliadin antibody 45
IgG antigliadin antibody 45 to 90
*–Average of costs at three reference laboratories
in the summer of 2001.
Information from references 21 through 23 and 25
Laboratory Evaluation of Patients
with Newly Diagnosed Celiac Disease
Complete blood cell count
Iron level, total iron-binding capacity determination, ferritin level *
Vitamin [B.sub.12] and folate levels
Calcium and phosphate levels
Alkaline phosphatase level
Blood urea nitrogen and creatinine levels
Albumin and total serum protein levels
Aspartate transaminase and alanine transaminase levels
Dual energy x-ray absorptiometry (DEXA) of spine and hip
Serologic tests ([dagger])
Quantitative IgA antiendomysial antibody or quantitative IgA
Quantitative IgA and IgG antigliadin antibodies
*–The ferritin level may be misleading: it may be elevated as an
([dagger])–Serologic testing should be recommended for first-degree
relatives of patients with newly diagnosed celiac
Celiac Sprue Association/United States of America, Inc. *
P.O. Box 31700, Omaha, NE 68131-0700
Web site: www.csaceliacs.org
E-mail address: email@example.com
Celiac Discussion List Archives
Web site: www.fastlane.net/homepages/thodge/ archive.shtml
National Digestive Diseases Information Clearinghouse
Web site: www.niddk.nih.gov/health/digest/pubs/celiac/index.htm
Celiac Disease Resources for Medical Professionals ([dagger])
Web site: www.uams.edu/celiac
*–The Celiac Sprue Association is a national organization that supports
persons with celiac disease and related
([dagger])–David A. Nelsen, Jr., M.D., M.S., maintains a Web site
with resources for primary care physicians to assist
them in the care of patients with celiac disease.
(1.) Ciclitira PJ, King AL, Fraser JS. AGA technical review on celiac sprue. American Gastroenterological Association. Gastroenterology 2001;120:1526-40.
(2.) Van De Wal Y, Kooy Y, Van Veelen P, Vader W, Koning F, Pena S. Coeliac disease: it takes three to tango! Gut 2000;46:734-7.
(3.) Marsh MN. The natural history of gluten sensitivity: defining, refining and re-defining. QJM 1995;88:9-13.
(4.) Sollid LM, Markussen G, Ek J, Gjerde H, Vartdal F, Thorsby E. Evidence for a primary association of celiac disease to a particular HLA-DQ alpha/beta heterodimer. J Exp Med 1989;169:345-50
(5.) Collin P, Salmi J, Hallstrom O, Reunala T, Pasternack A. Autoimmune thyroid disorders and coeliac disease. Eur J Endocrinol 1994; 130:137-40.
(6.) American Gastroenterological Association medical position statement: celiac sprue. Gastroenterology 2001;120:1522-25.
(7.) Catassi C, Ratsch IM, Fabiani E, Rossini M, Bordicchia F, Candela F, et al. Coeliac disease in the year 2000: exploring the iceberg. Lancet 1994;343:200-3.
(8.) Fasano A, Catassi C. Current approaches to diagnosis and treatment of celiac disease: an evolving spectrum. Gastroenterology 2001;120:636-51.
(9.) Hin H, Bird G, Fisher P, Mahy N, Jewell D. Coeliac disease in primary care: case finding study. BMJ 1999;318:164-7.
(10.) Branski D, Troncone R. Celiac disease: a reappraisal. J Pediatr 1998;133:181-7.
(11.) Not T, Horvath K, Hill ID, Partanen J, Hammed A, Magazzu G, et al. Celiac disease risk in the USA: high prevalence of antiendomysium antibodies in healthy blood donors. Scand J Gastroenterol 1998;33:494-8.
(12.) Cronin CC, Shanahan F. Insulin-dependent diabetes mellitus and coeliac disease. Lancet 1997;349:1096-7.
(13.) Iovino P, Ciacci C, Sabbatini F, Acioli DM, D’Argenio G, Mazzacca G. Esophageal impairment in adult celiac disease with steatorrhea. Am J Gastroenterol 1998;93:1243-9.
(14.) Clemens, PC. Coeliac disease in adults with atypical symptoms [Letter]. Lancet 1996;347:1050.
(15.) Ciacci C, Cirillo M, Sollazzo R, Savino G, Sabbatini F, Mazzacca G. Gender and clinical presentation in adult celiac disease. Scand J Gastroenterol 1995;30:1077-81.
(16.) Trier JS. Celiac sprue and refractory sprue. In: Feldman M, Fordtran JS, Sleisenger MH, Scharschmidt BF, eds. Sleisenger & Fordtran’s Gastrointestinal and liver disease: pathophysiology, diagnosis, management. 6th ed. Philadelphia: Saunders, 1998:1557-73.
(17.) Fine KD. The prevalence of occult gastrointestinal bleeding in celiac sprue. N Engl J Med 1996;334:1163-7.
(18.) Sher KS, Mayberry JF. Female fertility, obstetric and gynaecological history in coeliac disease. A case control study. Digestion 1994; 55:243-6.
(19.) Fotoulaki M, Nousia-Arvanitakis S, Augoustidou-Savvopoulou P, Kanakoudi-Tsakalides F, Zaramboukas T, Vlachonikolis J. Clinical application of immunological markers as monitoring tests in celiac disease. Dig Dis Sci 1999;44:2133-8.
(20.) Troncone R, Maurano F, Rossi M, Micillo M, Greco L, Auricchio R, et al. IgA antibodies to tissue transglutaminase: an effective diagnostic test for celiac disease. J Pediatr 1999;134:166-71.
(21.) Vitoria JC, Arrieta A, Arranz C, Ayesta A, Sojo A, Maruri N, et al. Antibodies to gliadin, endomysium, and tissue transglutaminase for the diagnosis of celiac disease. J Pediatr Gastroenterol Nutr 1999;29:571-4.
(22.) Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO, et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 1997;3:797-801.
(23.) Biagi F, Ellis HJ, Yiannakou JY, Brusco G, Swift GL, Smith PM, et al. Tissue transglutaminase antibodies in celiac disease. Am J Gastroenterol 1999;94:2187-92.
(24.) Russo PA, Chartrand LJ, Seidman E. Comparative analysis of serologic screening tests for the initial diagnosis of celiac disease. Pediatrics 1999;104(1 pt 1):75-8.
(25.) Valdimarsson T, Franzen L, Grodzinsky E, Skogh T, Strom M. Is small bowel biopsy necessary in adults with suspected celiac disease and IgA anti-endomysium antibodies? 100% positive predictive value for celiac disease in adults. Dig Dis Sci 1996;41:83-7.
(26.) Cataldo F, Marino V, Bottaro G, Greco P, Ventura A. Celiac disease and selective immunoglobulin A deficiency. J Pediatr 1997;131: 306-8.
(27.) Valdimarsson T, Lofman O, Toss G, Strom M. Reversal of osteopenia with diet in adult coeliac disease. Gut 1996;38:322-7.
(28.) Sategna-Guidetti C, Grosso SB, Grosso S, Mengozzi G, Aimo G, Zaccaria T, et al. The effects of 1-year gluten withdrawal on bone mass, bone metabolism and nutritional status in newly-diagnosed adult coeliac disease patients. Aliment Pharmacol Ther 2000; 14:35-43.
(29.) Dickey W. Epilepsy, cerebral calcifications, and coeliac disease. Lancet 1994;344:1585-6.
(30.) Hadjivassiliou M, Chattopadhyay AK, Davies-Jones GA, Gibson A, Grunewald RA, Lobo AJ. Neuromuscular disorder as a presenting feature of coeliac disease. J Neurol Neurosurg Psychiatry 1997;63: 770-5.
(31.) Hadjivassiliou M, Grunewald RA, Chattopadhyay AK, Davies-Jones GA, Gibson A, Jarratt JA, et al. Clinical, radiological, neurophysiological, and neuropathological characteristics of gluten ataxia. Lancet 1998;352:1582-5.
(32.) Pratesi R, Gandolfi L, Friedman H, Farage L, de Castro CA, Catassi C. Serum IgA antibodies from patients with coeliac disease react strongly with human brain blood-vessel structures. Scand J Gastroenterol 1998;33:817-21.
(33.) Pricolo VE, Mangi AA, Aswad B, Bland KI. Gastrointestinal malignancies in patients with celiac sprue. Am J Surg 1998;176:344-7.
(34.) Lewis HM, Renaula TL, Garioch JJ, Leonard JN, Fry JS, Collin P, et al. Protective effect of gluten-free diet against development of lymphoma in dermatitis herpetiformis. Br J Dermatol 1996; 135:363-7.
(35.) Holmes GK, Prior P, Lane MR, Pope D, Allan RN. Malignancy in coeliac disease–effect of a gluten free diet. Gut 1989;30:333-8.
(36.) Hoffenberg EJ, Haas J, Drescher A, Barnhurst R, Osberg I, Bao F, et al. A trial of oats in children with newly diagnosed celiac disease. J Pediatr 2000;137:361-6.
(37.) Janatuinen EK, Pikkarainen PH, Kemppainen TA, Kosma VM, Jarvinen RM, Uusitupa MI, et al. A comparison of diets with and without oats in adults with celiac disease. N Engl J Med 1995;333: 1033-7.
The author indicates that he does not have any conflicts of interest. Sources of funding: none reported.
Figure 1 provided by Laura Lamps, M.D., assistant professor of pathology, University of Arkansas for Medical Sciences (UAMS), Little Rock. Figure 4 provided by Bruce Smoller, M.D., professor of pathology and dermatology, UAMS.
DAVID A. NELSEN, JR., M.D., M.S., is associate professor in the Department of Family and Community Medicine at the University of Arkansas for Medical Sciences, Little Rock, where he earned his medical degree and completed a family medicine residency. He completed a faculty development and clinical investigation fellowship at the University of Minnesota Medical School, Minneapolis, where he also earned a master’s degree in family and community medicine. Dr. Nelsen has published and presented in the area of medical informatics and speech recognition. He serves on the technical panel of the American Academy of Family Physicians.
Address correspondence to David A. Nelsen Jr., M.D., M.S., University of Arkansas for Medical Sciences, Department of Family and Community Medicine, Mail Slot #530, 4301 W. Markham, Little Rock, AR 72205 (e-mail: firstname.lastname@example.org). Reprints are not available from the author.
COPYRIGHT 2002 American Academy of Family Physicians
COPYRIGHT 2003 Gale Group